Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2CNS 1

Conditions

Prostatic Neoplasms 20Urogenital Diseases 2Neoplasms 2Urinary Bladder Neoplasms 1Prostate Adenocarcinoma 1Neoplasm Metastasis 1Metastatic Castration-resistant Prostate Cancer 1Carcinoma, Transitional Cell 1

Interventions

pembrolizumab 28Docetaxel 21Gemcitabine 19Nivolumab 15Paclitaxel 13Prednisone 12Leuprolide 11pazopanib 10Radiotherapy 10Cisplatin 10Sunitinib 9Sorafenib 9Ipilimumab 8Blood Specimen Collection 8Bevacizumab 8avelumab 7atezolizumab 7Therapeutics 7Thalidomide 7Cyclophosphamide 7Carboplatin 7Standard of Care 6Radiation 6Mitomycin 6Interleukin-2 6Cetuximab 6Axitinib 6padeliporfin 5enzalutamide 5cemiplimab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms × fluciclovine F-18 × Genitourinary × Clear all
NCT03081884 2021-01-25

EDRN-FACBC

Emory University

Phase 2 Completed
61 enrolled 6 charts
Genitourinary

Urogenital Diseases, Neoplasm Metastasis, Neoplasms, Prostatic Neoplasms

NCT02830880 2020-01-07

FACBC Prostate Therapy Response

Emory University

Phase 2 Completed
7 enrolled 10 charts
Genitourinary

Urogenital Diseases, Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡